Clinical Trial Update: Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intravitreal ranibizumab for macular telangiectasia with neovascularization has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Telangiectasia | Phase 1 | Status: COMPLETED